Document Detail


Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma.
MedLine Citation:
PMID:  20807093     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We conducted a retrospective cohort study examining the influence of obesity on treatment outcome and survival among 712 patients with intermediate-grade B-cell NHL receiving frontline therapy between 1988 and 2001. Baseline adiposity was approximated by body mass index categorized according to the World Health Organization schema. Logistic and Cox proportional hazards regression modeling was used to adjust for baseline patient demographic, disease, and treatment variables. Approximately 37% of cohort patients were overweight (BMI 25 to <30 kg/m(2)) and more than 23% were obese (BMI >or= 30 kg/m(2)). Risk factors were similar across groups and treatment intensity did not vary by BMI. Median follow-up was 45.7 and 62.8 months for PFS and OS, respectively. After adjustment for other significant prognostic factors, BMI in the overweight range was associated with significantly reduced hazard for both PFS (OR 0.72, p = 0.011) and OS (OR 0.74, p = 0.030). Increased BMI is associated with significantly improved survival among patients with treatment-naive, intermediate-grade B-cell NHL. Prospective confirmation of these results is warranted given the increasing prevalence of both NHL and obesity.
Authors:
Jeffrey A Jones; Luis E Fayad; Linda S Elting; Maria A Rodriguez
Related Documents :
22194023 - Lhermitte sign and myelopathy after irradiation of the cervical spinal cord in radiothe...
1730123 - Primary non-hodgkin's lymphomas of the female breast.
6685213 - Enhanced tumor growth in experimental whole body hyperthermia.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  51     ISSN:  1029-2403     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-02     Completed Date:  2010-12-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  England    
Other Details:
Languages:  eng     Pagination:  1649-57     Citation Subset:  IM    
Affiliation:
Division of Hematology-Oncology, Department of Internal Medicine, Ohio State University College of Medicine, Columbus, OH 43210, USA. jeffrey.jones@osumc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Body Composition
Body Mass Index*
Cohort Studies
Female
Follow-Up Studies
Humans
Lymphoma, Follicular / drug therapy*,  mortality,  pathology
Lymphoma, Large B-Cell, Diffuse / drug therapy*,  mortality,  pathology
Male
Middle Aged
Neoplasm Staging
Obesity / complications*
Overweight
Prognosis
Retrospective Studies
Survival Rate
Comments/Corrections
Comment In:
Leuk Lymphoma. 2010 Sep;51(9):1590-1   [PMID:  20807091 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic markers in diffuse large B-cell lymphoma.
Next Document:  Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regim...